Development asset linked to NeuroSense Therapeutics in public FDA and regional records.
pharma · Amyotrophic Lateral Sclerosis · Pharmacokinetics · NRSN
NeuroSense Therapeutics
NeuroSense Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2017 Founded
30 Employees
Public company Type
NRSN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 30
- Programs
- 6
- Drugs
- 6
- Patents
- 2
NeuroSense Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
NeuroSense Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to NeuroSense Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor